GHK-Cu

GHK-Cu (Copper Peptide GHK-Cu, Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a naturally occurring tripeptide-copper(II) complex first identified in human plasma in 1973 by Dr. Loren Pickart. Its plasma concentration decreases significantly with age — from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — paralleling the decline in tissue regenerative capacity. GHK-Cu is one of the most extensively studied regenerative compounds, with research demonstrating its involvement in over 4,000 gene expression changes, many of which reset gene expression patterns toward a younger, healthier state. Documented research effects include stimulation of collagen I, III, and V synthesis, upregulation of decorin (a collagen-organizing proteoglycan), increased production of metalloproteinases for ECM remodeling, enhancement of superoxide dismutase (SOD) and other antioxidant enzymes, promotion of angiogenesis and nerve outgrowth, anti-inflammatory activity through IL-6 and TNF-α suppression, stimulation of glycosaminoglycan synthesis in fibroblasts, attraction of immune cells and mesenchymal stem cells to wound sites, and hair follicle growth stimulation through Wnt/β-catenin pathway activation. This 1500 mg format supports large-scale in-vitro studies, formulation development, and multi-condition experimental designs.